First-in-human Study of ATX-898, as Monotherapy and in Combination With Other Anti-neoplastic Agents, in Participants With Advanced Solid Tumors
Considering participating in a START clinical trial?
Study Summary
Study ATX-898-101 is a phase 1/2 open-label study evaluating the safety, tolerability, pharmacokinetic, and preliminary efficacy of ATX-898 as monotherapy and in combination with anti-neoplastic agents in selected solid tumors. This study consists of 2 parts. Part 1 evaluates ATX-898 as monotherapy and Part 2 evaluates ATX-898 in combination with anti-neoplastic agents of interest. Both parts will consists of a dose escalation portion and a dose expansion portion.
Main objective (English)
Part 1A: Evaluate the overall safety and tolerability of ATX-898 administered as monotherapy and determine the MTD (or maximum tested dose) and recommended dose for expansion (RDE); Part 1B: Assess the antitumor activity of ATX-898 administered as monotherapy in participants in each expansion cohort; Part 2A: Determine the RDE of ATX-898 in combination with fulvestrant and abemaciclib (Part 2A1) and/or fulvestrant and ribociclib (Part 2A2); Part 2B: Further assess the antitumor activity of ATX-898 at the combination RDE in combination with fulvestrant and abemaciclib (Part 2B1) and/or ribociclib (Part 2B2)
- * Has histologically or cytologically confirmed advanced solid tumor malignancy that is metastatic or locally advanced and unresectable * Is ≥18 years of age at the time of signing the informed consent form * ECOG performance status score of 0 or 1 * Adequate organ function * Must consent to a pre-treatment tumor biopsy (collected during screening or have available archival tumor tissue in the past 5 years. For Part 1a (monotherapy dose escalation) * Has received one or more standard systemic therapies and additional standard therapies are either not available, or participant ineligible for available standard therapies For Part 1b (monotherapy dose expansion) * b1: Has platinum-resistant or refractory metastatic ovarian cancer * b2: Has recurrent or metastatic gynecologic cancer excluding the cancers eligible for b1 * b3: Has recurrent advanced or metastatic solid tumor excluding the cancers eligible for b1 or b2 * Has at least 1 measurable lesion per RECIST 1.1 For Part 2a (combination dose escalation) * Has confirmed HR+ HER2 - (including HER2 low and ultra low) status * Has received prior therapy in the metastatic For Part 2b (combination dose expansion) * Has confirmed HR+ HER2 - (including HER2 low and ultra low) status * Treatment-naïve or has received prior therapy in the metastatic setting
- as per ctis:
- Has histologically or cytologically confirmed advanced solid tumor malignancy that is metastatic or locally advanced and unresectable
- Male participant (with a successful vasectomy) and his female partner(s) who are of childbearing potential must agree to consistently use 1 barrier method (e.g., condom with spermicidal foam/gel/film/cream/suppository) starting at Screening and continuing throughout the study period and for at least 90 days after the last dose of ATX-898 for monotherapy treatment and at least 2 years after the last dose of fulvestrant for fulvestrant combination treatment.
- Has adequate organ function as defined by the protocol
- Male participant with a pregnant partner must consistently use a condom to prevent potential fetal exposure.
- Participant, or legally authorized representative if applicable, is capable of understanding the written ICF and other patient-facing study materials, provides signed and witnessed written informed consent, and agrees to comply with protocol requirements.
- [Part 1A] Has received one or more standard systemic therapies and additional standard systemic therapies are either not available, contraindicated, or the participant is deemed by the Investigator to not be an appropriate candidate for available standard therapy option(s)
- [Part 1A] For participants with solid tumors other than breast cancer, has protocol required biomarker positive status. For participants with HR+/HER2- breast cancer, must have HR+/HER2–, HR+/HERlow (as defined by a HER2 IHC score of 1+ or by a score of 2+ with a negative FISH determined in a CLIA-certified or locally equivalent clinical laboratory), or HR+/HERultralow (as defined by HER2 IHC 0 with membrane staining determined in a CLIA-certified or locally equivalent clinical laboratory).
- Is ≥18 years of age at the time of signing the informed consent form (ICF)
- Has ECOG performance status score of 0 or 1
- Must consent to a pre-treatment tumor biopsy (collected during screening) or have available archival tumor tissue in the past 5 years. On-treatment biopsies are optional.
- Before study entry, a female must meet one of the following, or according to local regulations: a) be of nonchildbearing potential, defined as per protocol; b) Be a female of childbearing potential (FCBP; any female participant who does not meet the nonchildbearing criteria above) who agrees to remain on 1 highly effective method and 1 additional effective (barrier) method of contraception from initiation of study treatment, throughout the study and for at least 6 months after the last dose of ATX-898 for monotherapy treatment. For combination treatment, the participant must agree to use 1 highly effective method and 1 additional effective barrier method (e.g., condom with spermicidal foam/gel/film/cream/suppository) of contraception throughout the study for at least 2 years after the last dose of fulvestrant for fulvestrant combination treatment or at least 6 months after the last dose of ATX-898 if fulvestrant has not been part of the combination treatment.
- [Part 1B] Has protocol required biomarker positive status.
- A female participant must agree to refrain from donating eggs (ova, oocytes) for the purpose of assisted reproduction from initiation, during the study and for a period of at least 6 months after the last dose of ATX-898 for monotherapy treatment and at least 2 years after the last dose of fulvestrant for fulvestrant combination treatment.
- A FCBP must have a negative, highly sensitive serum (β-human chorionic gonadotropin) pregnancy test at Screening.
- Female participants must agree not to breastfeed starting at Screening, throughout the study period, and for at least 6 months after the last dose of ATX-898 for monotherapy treatment and at least 2 years after the last dose of fulvestrant for fulvestrant combination treatment.
- [Part 1A] For participants with HR+/HER2- breast cancer, participants must have received prior systemic therapy - can be in the adjuvant or metastatic setting
- [Part 1A] For backfill cohorts: must have at least 1 measurable lesion per RECIST 1.1. Note: Previously irradiated lesion may only be counted as a target lesion if there is clear progression since the irradiation.
- Male participant (without vasectomy) whose female partner(s) is/are of childbearing potential must agree to do the following: a) Use 2 forms of contraception consistently (at least 1 of which must be a barrier method [e.g., condom with spermicidal foam/gel/film/ cream/suppository], and the other of which must be a highly effective method of contraception) starting at Screening and continuing throughout the study period and for at least 90 days after the last dose of ATX-898 for monotherapy treatment and at least 2 years after the last dose of fulvestrant for fulvestrant combination treatment. b) Refrain from donating sperm from Day 1 until at least 90 days after the final administration of ATX-898 and at least 2 years after the last dose of fulvestrant for fulvestrant combination treatment.
- [Part 1B] Cohort B2 and B3 only: Must have received systemic therapy
- [Part 1B] Cohort B2 only: Has recurrent or metastatic cancer
- [Part 1B] Cohort B3 only: Has an advanced or refractory solid tumor malignancy of a cancer type not included in other inclusion criteria
- [Part 1B] Must have at least 1 measurable lesion per RECIST 1.1 Note: Previously irradiated lesion may only be counted as a target lesion if there is clear progression since the irradiation.
- Has history (within ≤2 years before screening) of a solid tumor or hematological malignancy that is histologically distinct from the cancer being studied * Has symptomatic CNS metastases at screening or asymptomatic CNS metastases requiring corticosteroids to control symptoms within 28 days prior to the first dose of ATX-898. * Has toxicities from previous anticancer therapies that have not resolved to baseline levels or to CTCAE Grade ≤1, with the exception of alopecia any grade and Grade ≤2 peripheral neuropathy * Has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the participant or would prevent, limit, or confound the protocol-specified assessments Cohort Specific: * For abemaciclib cohorts only: has a history of any events of cardiac etiology that would contraindicate dosing with abemaciclib * For ribocicilib only: has history of pneumonitis or interstitial lung disease
- as per ctis:
- Has had prior organ transplantation.
- Has a history of or a suspected allergy or hypersensitivity to ATX-898, other study treatments, or their excipients; hypersensitivity to peanut (ribociclib cohorts only).
- Has any condition requiring systemic corticosteroids (daily prednisone equivalent doses not exceeding a total dose of 140 mg over the past 14 days) or other immunosuppressive therapy within 2 weeks prior to the start of study treatment. Note: Inhaled, intranasal, intra-articular, or topical steroids are permitted. Transient short-term use of systemic corticosteroids for transient conditions (e.g., allergic conditions, asthma/chronic obstructive pulmonary disease (COPD) exacerbations, contrast allergy) is permitted.
- Has known, uncontrolled human immunodeficiency virus (HIV)-1 infection or acquired immunodeficiency syndrome (AIDS), with the following exceptions: • Participants with known HIV infection are permitted if they have controlled infection (undetectable viral load [HIV ribonucleic acid (RNA) polymerase chain reaction (PCR)] and CD4 count ≥350 cells/μL either spontaneously or on a stable antiviral regimen). For participants with controlled HIV infection, monitoring will be performed per local standards. • Participants with AIDS who have not experienced an opportunistic infection in the past 12 months may be eligible with Medical Monitor approval.
- Has positive hepatitis B surface antigen or hepatitis C virus (HCV) antibody (anti-HCV) test, clinically active or chronic liver diseases, including liver cirrhosis of Child-Pugh Class C. Note: Participants with treated hepatitis B or C and positive antibody test are eligible only if followed by a negative RNA test (i.e., viral load below the limit of quantification or on a stable antiviral regimen).
- Has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrythmia, or psychiatric illness/social situation that would limit compliance with study requirements. Note: Participants with a history of myocardial infarction, unstable angina, or acute coronary syndrome within the 6 months prior to enrollment are excluded.
- Has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the participant or would prevent, limit, or confound the protocol-specified assessments (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn’s disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
- For abemaciclib cohorts only: The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
- For ribociclib cohorts only: History of pneumonitis or interstitial lung disease.
- Has received prior treatment with treatment directed at the protocol defined target.
- For ribociclib cohorts only: Participant currently receiving any of the following substances and cannot discontinue them 7 days prior to Cycle 1 Day 1 (C1D1): • Concomitant medication(s) with a known risk to prolong the QT interval and/or known to cause Torsades de Pointes (TdP) that cannot be discontinued or replaced by safe alternative mediation (e.g., within 5 half-lives or 7 days before starting study drug) are not permitted • Concomitant medications, herbal supplements, and/or fruits (e.g., grapefruit, pummelos, star fruit, Seville oranges) and their juices that are strong inducers or inhibitors of cytochrome P450 3A4/5 (CYP3A4/5) • Medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5
- Has toxicities from previous anticancer therapies that have not resolved to baseline levels or to CTCAE Grade ≤1, with the exception of alopecia any grade and Grade ≤2 peripheral neuropathy.
Clinical Study Information for Healthcare Providers
By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.